<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038998</url>
  </required_header>
  <id_info>
    <org_study_id>CIBIR002</org_study_id>
    <nct_id>NCT02038998</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients</brief_title>
  <official_title>Unicentric, Phase II, Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Rioja Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital San Pedro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Rioja Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is one of the leading causes of death and disability worldwide. More than 85% of&#xD;
      strokes are due to blood vessel occlusion resulting in partial destruction of the brain&#xD;
      parenchyma. Current protocols try to re-establish blood circulation as soon as possible&#xD;
      through chemical and/or mechanical interventions but new strategies are needed.&#xD;
&#xD;
      Periodic acceleration (pGz) is a non-invasive method consisting in the application of a&#xD;
      rocking movement to the patient that ultimately will induce the release of beneficial&#xD;
      chemicals from the vascular endothelium (the cells lining the inside of the blood vessels).&#xD;
      Application of pGz in an animal model of stroke resulted in a dramatic reduction of&#xD;
      associated brain damage.&#xD;
&#xD;
      This trial will investigate whether stroke patients exposed to pGz experiment significantly&#xD;
      higher recovery than patients that remained static during their treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periodic acceleration (pGz) is a non-invasive method consisting in the application of a&#xD;
      rocking movement to the patient that ultimately will induce the release of beneficial&#xD;
      chemicals from the vascular endothelium (the cells lining the inside of the blood vessels).&#xD;
      Application of pGz in an animal model of stroke resulted in a dramatic reduction of&#xD;
      associated brain damage.&#xD;
&#xD;
      This trial will investigate whether stroke patients exposed to pGz experiment significantly&#xD;
      higher recovery than patients that remained static during their treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Lack of available patients&#xD;
  </why_stopped>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NIHSS and Rankin scales</measure>
    <time_frame>0hr, 2hr, 24hr, 48hr, 7ds, 90ds</time_frame>
    <description>The NIHSS and Rankin scales will be applied to the patients at the indicated times</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct volume</measure>
    <time_frame>7 days</time_frame>
    <description>Infarct volume will be measured by nuclear magnetic resonance 7 days after stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood markers</measure>
    <time_frame>0, 1, 3, 5, and 7ds</time_frame>
    <description>Neuroprotective substances that can be released by pGz (nitric oxide, tissue plasminogen activator, adrenomedullin, prostaglandins, etc) will be measured in the blood of patients to investigate the efficacy of the treatment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Cerebrovascular Stroke</condition>
  <arm_group>
    <arm_group_label>Static group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single pGz intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple pGz interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exer-Rest® TL</intervention_name>
    <description>Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.</description>
    <arm_group_label>Multiple pGz interventions</arm_group_label>
    <arm_group_label>Single pGz intervention</arm_group_label>
    <arm_group_label>Static group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A signed informed consent form must be obtained prior to recruitment&#xD;
&#xD;
          -  Patients with symptoms of acute ischemic stroke&#xD;
&#xD;
          -  Less than 12 hours from initiation of the stroke&#xD;
&#xD;
          -  Age: 18 years or older&#xD;
&#xD;
          -  Capable of following the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women, and women that do not follow a contraceptive plan and may&#xD;
             become pregnant&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  More than 12 hours from the initiation of the stroke or when the initiation time is&#xD;
             unknown.&#xD;
&#xD;
          -  Hemorrhagic stroke&#xD;
&#xD;
          -  Candidates to receive thrombolytic treatment&#xD;
&#xD;
          -  Spine traumatism or other conditions that may be aggravated by pGz&#xD;
&#xD;
          -  Patients that cannot be properly followed because of phycological, social, familiar,&#xD;
             or geographical reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Julian-Villaverde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Pedro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Martinez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion Rioja Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <state>La Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Martínez-Murillo R, Serrano J, Fernández AP, Martínez A. Whole-body periodic acceleration reduces brain damage in a focal ischemia model. Neuroscience. 2009 Feb 18;158(4):1390-6. doi: 10.1016/j.neuroscience.2008.12.005. Epub 2008 Dec 14.</citation>
    <PMID>19135137</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Rioja Salud</investigator_affiliation>
    <investigator_full_name>Alfredo Martinez</investigator_full_name>
    <investigator_title>Group Leader</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>periodic acceleration</keyword>
  <keyword>endothelium release</keyword>
  <keyword>ischemic penumbra</keyword>
  <keyword>shear stress</keyword>
  <keyword>adrenomedullin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

